Dalbavancin for Recurrent MRSA and Group A Streptococcus Cellulitis

Patient Selection and Treatment

• The Infectious Diseases Society of America recommends coverage for both MRSA and Group A Streptococcus in patients with confirmed infection, such as this patient with recurrent right lower leg cellulitis, 1, 2
• Patients with multiple risk factors, including history of recurrent infections, chronic wounds, and complex psychosocial factors, may benefit from dalbavancin treatment, 2, 3

Antimicrobial Coverage and Efficacy

• Dalbavancin provides dual coverage for MRSA and Group A Streptococcus, with clinical success rates of 86.1% for MRSA and 92.9% for Streptococcus pyogenes, 2
• The American College of Clinical Pharmacy recommends dalbavancin as an option for treating acute bacterial skin and skin structure infections caused by susceptible gram-positive organisms, including MRSA and Streptococcus pyogenes, 1, 2

Alternative Options

• Alternative treatment options for hospitalized patients with complicated skin infections include IV vancomycin, IV/oral linezolid, and IV daptomycin, all with A-I evidence, 1, 2
• The Infectious Diseases Society of America recommends considering the patient's psychosocial circumstances and the potential need for prolonged hospitalization or reliable outpatient follow-up when selecting an alternative treatment option, 1, 2